Correlation of prognosis with the gradually increased Golgi protein 73 expression in the progression of benign liver diseases to precancerous lesions and hepatocellular carcinoma.

Abstract

e15050 Background: Serum golgi protein73 (sGP73) is a novel biomarker for hepatocellular carcinoma (HCC). However, there are few reports on the pattern of GP73 expression in the progression of benign liver diseases to precancerous lesions and HCC. This study aimed to investigate GP73 expression and it correlation with clinicopathologic parameters. Methods: Tissue GP73 (tGP73) levels were detected in specimens of group A (n=186) including HCC (n=62), peritumoral tissue (PTL) (n=43), high/low-grade hepatic atypical hyperplasia (AH) (n=32/2), chronic hepatitis B (CHB) (n=42) and normal controls (NC) (n=5) by immunohistochemistry, and GP73 expression in group B (n=159) and group C (n=16) were detected by RT-PCR and Western blot respectively. sGP73 levels were detected in subjects of group D (n=287) by ELISA. Results: GP73 expression increased gradually from NC, CHB, PTL to high-grade AH and HCC at both protein and mRNA levels (P<0.05), while sGP73 in HCC group was lower than in liver cirrhosis (LC) group (P<0.001). Both tGP73 and sGP73 levels were negatively associated with tumor size and TNM stage, and tGP73 levels were positively associated with tumor differentiation. The high-tGP73 group showed significantly better overall and disease-free survival than low-tGP73 group (P=0.008, P=0.018). Multivariate analysis revealed that the tGP73 level was an independent prognostic factor for HCC, but not sGP73. Conclusions: GP73 increases gradually in the progression ofbenign liver diseases to precancerous lesions and HCC. This expression pattern suggests the regulatory mechanism of GP73 is related to the progression of chronic liver diseases. Furthermore, a high level of tGP73 is a favorable prognostic factor for HCC.

Golgi protein 73 and its diagnostic value in liver diseases

“…These results indicate that hepatocytes undergo some transformation when liver diseases occur, altering some of the factors that regulate the expression of GP73. Studying these regulatory mechanisms will thus help to understand pathogenesis of liver diseases …”

“…Studying these regulatory mechanisms will thus help to understand pathogenesis of liver diseases. [130][131][132][133][134][135][136]…”

“…Moreover, GP73 tends to be used as a useful biomarker to monitor HCC prognosis after primary tumour surgery and therapy in advanced HCC. 132,133 In terms of clinical application, it is still a new biomarker, and large-scale and multi-centred investigations are still needed. Moreover, more sensitive, specific and rapid diagnostic methods are also needed.…”

“…It still needs further research about the significance of HCC‐specific GP73 isoform in diagnostic accuracy improvement. Moreover, GP73 tends to be used as a useful biomarker to monitor HCC prognosis after primary tumour surgery and therapy in advanced HCC . In terms of clinical application, it is still a new biomarker, and large‐scale and multi‐centred investigations are still needed.…”